血管内皮抑素抗肿瘤研究进展  

Advance in research on anti-tumor of endostatin

作　　者：张志明[1] 于静萍[1] 孙苏平[1] 

机构地区：[1]南京医科大学附属常州第二人民医院放疗科,常州213003

出　　处：《国际肿瘤学杂志》2011年第5期345-348,共4页Journal of International Oncology

摘　　要：血管内皮抑素是一种广谱的抗血管生成分子靶向物，其通过抑制肿瘤形成过程的病理性血管生成及抑制肿瘤细胞增殖和转移，发挥抗肿瘤作用。近年来随着靶向治疗药物不断进入临床，血管内皮抑素成为肿瘤综合治疗研究的热点之一。Endostatin is an antitumor molecular targeting angiogenesis of tumor and plays an inhibitory role in tumorigenesis through inhibiting pathological angiogenesis, proliferation and metastasis of tumor. As increasing drugs for targeting therapy aim in clinic, endostatin has become one of hot spots of research on combined treatment of cancer in recent years.

关 键 词：内皮抑素类 肿瘤 靶向治疗 

分 类 号：R730.2[医药卫生—肿瘤]